ACI
SRPT icon

AMP Capital Investors’s Sarepta Therapeutics SRPT Stock Holding History

AMP Capital Investors’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-13,673
Closed -$1.02M – 1236
2021
Q1 		$1.02M Buy
13,673
+300
+2% +$27.7K 0.01% 850
2020
Q4 		$2.29M Buy
13,373
+241
+2% +$35.7K 0.01% 734
2020
Q3 		$1.85M Sell
13,132
-7,964
-38% -$1.21M 0.01% 728
2020
Q2 		$3.43M Sell
21,096
-7,349
-26% -$1M 0.02% 601
2020
Q1 		$2.8M Sell
28,445
-894
-3% -$102K 0.02% 599
2019
Q4 		$3.78M Buy
29,339
+13,135
+81% +$1.33M 0.02% 632
2019
Q3 		$1.22M Buy
+16,204
New +$1.91M 0.01% 842

Other funds holding SRPT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

AMP Capital Investors's SRPT Position: Q2 2021 in Review

AMP Capital Investors sold out of Sarepta Therapeutics (SRPT) in Q2 2021, closing a stake of 13,673 shares — an estimated $1.02M sold.

AMP Capital Investors first reported a position in SRPT in Q3 2019 and held it in 7 quarters. The position peaked at $3.78M in Q4 2019. 330 funds tracked by Wall St. Rank hold SRPT as of Q2 2021.

  • AMP Capital Investors reported no remaining Sarepta Therapeutics position as of Q2 2021 after selling out during the quarter.
  • AMP Capital Investors sold 13,673 Sarepta Therapeutics shares in Q2 2021, an estimated $1.02M.
  • AMP Capital Investors first reported a position in Sarepta Therapeutics in Q3 2019 and held it in 7 quarters.
  • AMP Capital Investors's Sarepta Therapeutics position peaked at $3.78M in Q4 2019.
  • 330 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2021.

Based on AMP Capital Investors's 13F filing for Q2 2021, filed 16 Aug 2021.